Decoy Therapeutics Inc Dossier - Source-backed chat

Decoy Therapeutics Inc

DCOYNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.85Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.2M

Shares Outstanding 655.2K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Decoy Therapeutics Inc. (NASDAQ: DCOY) is a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a novel category of therapeutics engineered to target shared viral mechanisms conserved across virus families. Built on its proprietary IMP3ACT peptide-conjugate platform, Decoy's approach moves beyond the traditional 'one-virus, one-drug' model to address broad respiratory threats. The company has established strategic relationships with Google Cloud, Quantori, and the Gates Foundation, and recently secured a structured PIPE financing of up to $21 million. While the company is in its early preclinical stages with a micro-cap valuation, its highly differentiated platform and structured milestone-based funding provide a compelling high-risk, high-reward opportunity for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$30.00

Mean target$30.00

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$30.0020%

Preclinical development or IND-enabling studies face unexpected delays, or the company fails to obtain regulatory approvals for its clinical trials in the EEA or UK. Consequently, the milestone-based warrants expire unexercised, leaving the company with limited cash reserves and forcing highly dilutive equity raises or halting pipeline development.

Base CaseCentral scenario

$30.0055%

Matches the consensus mean

Decoy executes on its 2026-2027 roadmap, utilizing its $3.5 million upfront PIPE proceeds to complete IND-enabling studies. The company initiates its Phase 1 clinical trial for DCOY-COV in 2027 as planned. Milestone warrants are partially exercised as clinical milestones are met, providing steady capital to advance the DCOY-TRI program. The stock moves toward the consensus analyst target as clinical validation emerges.

Bull CaseUpside scenario

$30.0025%

The IMP3ACT platform successfully delivers rapid candidate selection, and the lead DCOY-COV program enters Phase 1 trials ahead of schedule in early 2027. Positive Phase 2a human challenge data in the UK triggers the full exercise of Series A, B, and C warrants, injecting $17.5 million in non-dilutive milestone cash. Strategic partnerships with major pharmaceutical companies or global health organizations validate the platform, driving substantial valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pioneering D-MAV platform (IMP3ACT) capable of targeting multiple viral families with a single drug.
Structured PIPE financing providing up to $21 million, directly tied to clinical execution milestones.
Strong external validation through collaborations with Google Cloud, Quantori, and the Gates Foundation.
High-value target markets addressing significant unmet needs in immunocompromised populations.

Key Investment Risks

Preclinical-stage risk with no assets currently in clinical trials.
Extremely small market capitalization and high stock price volatility.
Dependence on meeting strict clinical milestones to unlock the remaining $17.5 million of the PIPE financing.
Historical cash burn and ongoing net losses.

Thesis Invalidation Triggers

Failure to file a Clinical Trial Application (CTA) for Phase 1 trials by late 2027.
Inability to secure stockholder approval for the milestone-based warrants.
Negative safety or efficacy signals in preclinical animal models.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.